Sofia Fund

Strategikon Launches Clinical Maestro® 5.0

by | Aug 27, 2025 | Portfolio Company News

Strategikon, a leader in clinical trial outsourcing and vendor management solutions, has announced the launch of Clinical Maestro® 5.0, a major upgrade designed to help sponsors and CROs make faster, smarter outsourcing decisions. Revolutionizing vendor management with instant insights, compliance control, and transparency all while bringing AI-powered intelligence to clinical outsourcing, Clinical Maestro AI, is an intelligent companion that turns static documents into instant insights—decoding files, summarizing vendor performance, and pulling historical context to cut hours of manual work.…

Respin and Joylux Announce Strategic Partnership

by | Sep 24, 2024 | Portfolio Company News

Joylux, the global leader in intimate wellness, and Respin, the women’s midlife wellness brand founded by Academy Award-winning actress, filmmaker, entrepreneur and advocate Halle Berry, announce a global multi-facetted partnership to bring solutions to the 60 million peri/post-menopausal women suffering from common intimate health issues.…

ACA Honors Angel-Financed Innovation with the Prestigious Luis Villalobos Award

by | May 19, 2022 | Portfolio Company News

Atlantic City, NJ (May 19, 2022) – Recognizing the most ingenious and innovative ideas recently financed by members of the Angel Capital Association, the prestigious Luis Villalobos Award was recently awarded to two companies disrupting their fields. Recognized were Healionics, a company making dialysis safer for those in kidney failure in the Life Sciences category, and Tilt, a company revolutionizing employee leave management in the workplace, in the Technology, Services and Consumer category.…

Cognition Therapeutics has a transformative 2021 with positive performance addressing age related degenerative diseases and disorders of the central nervous system.

by | Jan 10, 2022 | Portfolio Company News

Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022

PURCHASE, N.Y., Jan. 10, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.…